AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Stocksdownunder

Published November 5, 2026

Compass Pathways (NDQ: CMPS): Can Psychedelic Therapy Become Mainstream Medicine ...

Read the full story at Stocksdownunder

The question of whether psychedelic therapies can produce meaningful effects in depression has been settled. Now the question is whether healthcare.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
Psychedelic biotech